Intelligent Bio Solutions Expects to Report Fiscal Second Quarter 2026 Revenue Growth of Approximately 48% Year-Over-Year, Surpassing $2 Million in Total Revenue for First Half of Fiscal Year
MWN-AI** Summary
Intelligent Bio Solutions Inc. (Nasdaq: INBS) has announced its expectations for strong revenue growth in its fiscal second quarter and first half of 2026, with estimates indicating a remarkable 48% year-over-year increase in Q2 revenue, pushing total revenue for the first half above $2 million. This anticipated surge is attributed to a growing customer base and robust demand across all product categories, particularly highlighting significant gains in reader sales, which are projected to exceed 100% growth year-over-year.
For the six-month period ending December 31, 2025, the company expects to generate approximately $2.01 million in total revenue, marking a 36% increase compared to the same period in the previous year. Specific growth metrics include a 38% increase in cartridge sales, a 50% rise in reader sales, and a 10% increase in sales from accessories and training services. During Q2 alone, the results were even more striking, with cartridge sales witnessing a 33% growth and reader sales more than doubling.
Harry Simeonidis, President and CEO of Intelligent Bio Solutions, expressed optimism regarding these results, emphasizing that the company’s "razor-razorblade" business model is proving effective. As the installed base of readers expands, it fosters long-term relationships and sustained recurring cartridge revenue, which is crucial for future growth.
The figures, while preliminary and subject to adjustments upon the completion of financial processes, underscore the company's solid commercial strategy and its potential to capture greater market share within the rapidly evolving medical technology landscape. The finalized financial results are expected to be reported in the company's forthcoming Quarterly Report on Form 10-Q.
MWN-AI** Analysis
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is poised for significant growth as it reports expected fiscal second-quarter revenue enhancement of approximately 48% year-over-year. This confidence, spurred by an expanding customer base and robust performance across all product lines, suggests that INBS is on track to exceed $2 million in total revenue for the first half of fiscal 2026. Notably, the reader sales are projected to double year-over-year, reflecting a compelling adoption of their Intelligent Fingerprinting Drug Screening System.
From an investment perspective, INBS's trajectory appears promising, particularly as it operates under a "razor-razorblade" model. This model not only encourages initial sales but fosters recurring revenue through ongoing cartridge sales as new readers are deployed. The expected growth in cartridge sales by around 33% underscores the company’s capacity for sustainable income, with management indicating a strong confidence in capturing greater market share driven by successful commercialization strategies.
Investors should consider this announcement an endorsement of Intelligent Bio's potential to innovate within the medical technology space, particularly in non-invasive testing solutions. Positioned in vital customer sectors such as construction and transport, INBS's products are suited to meet increasing demands for workplace safety, further solidifying their market standing.
However, while the preliminary results are promising, potential investors should remain wary of the inherent risks involved in the healthcare sector, including regulatory hurdles and competitive pressures. Therefore, while INBS exhibits solid growth prospects based on emerging revenue trends, careful consideration of the broader market landscape and associated risks is essential for informed investment decisions. Overall, this growth trajectory presents a compelling case for considering a position in INBS, albeit with prudent risk management practices.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Expected record fiscal second quarter revenue increase driven by expanding customer base and strong growth across all product categories
Reader sales expected to post year-over-year growth of more than 100% in fiscal Q2, expanding installed base to drive sustained recurring cartridge revenue
NEW YORK, Feb. 05, 2026 (GLOBE NEWSWIRE) -- Intelligent Bio Solutions Inc. (Nasdaq: INBS) ("INBS" or the "Company"), a medical technology company delivering intelligent, rapid, non-invasive testing solutions, today announced preliminary, unaudited revenue results for the fiscal second quarter and first half 2026 ended December 31, 2025.
The Company expects to report strong revenue growth across all product categories for the three- and six-month periods ended December 31, 2025.
Six-Month Period (Fiscal H1 ’26, July - December 2025):
- Total revenue expected to be approximately $2.01 million, representing a 36% increase year-over-year
- Sales of cartridges expected to increase approximately 38% year-over-year
- Sales of readers expected to increase approximately 50% year-over-year
- Other sales (accessories, training) expected to increase approximately 10% year-over-year
Three-Month Period (Fiscal Q2 ’26, October - December 2025):
- Revenue expected to increase approximately 48% year-over-year
- Sales of cartridges expected to increase approximately 33% year-over-year
- Sales of readers expected to more than double, increasing approximately 104% year-over-year
- Other sales (accessories, training) expected to increase approximately 36% year-over-year
“We are very pleased with our expected results, showing strong second-quarter performance and reader sales more than doubling year-over-year," said Harry Simeonidis, President and CEO at Intelligent Bio Solutions. "This expansion of our installed base is the foundation of our razor-razorblade business model, as each reader placement creates a long-term relationship that drives recurring cartridge revenue. The anticipated 33% growth in cartridge sales demonstrates this model in action, reflecting new customer adoption and ongoing consumable demand. Momentum across all product categories reinforces our confidence in the commercial strategy and our ability to capture greater market share. As our installed reader base continues to grow, we are strengthening the foundation for recurring revenue growth throughout fiscal 2026 and beyond."
The preliminary unaudited revenue results for the fiscal second quarter and first half 2026, ended December 31, 2025, are based on information available to management as of the date of this press release and are, therefore, subject to adjustments based on the Company’s completion of its quarter-end financial close process. The Company expects to disclose financial results for the fiscal second quarter and first half 2026 ended December 31, 2025, in its upcoming Quarterly Report on Form 10-Q, expected to be filed with the Securities and Exchange Commission during the week commencing February 09, 2026.
About Intelligent Bio Solutions Inc.?
Intelligent Bio Solutions Inc. (NASDAQ: INBS) is a medical technology company delivering intelligent, rapid, non-invasive testing solutions. The Company believes that its?Intelligent Fingerprinting Drug Screening System?will revolutionize portable testing through fingerprint sweat analysis, which has the potential for broader applications in additional fields. Designed as a hygienic and cost-effective system, the test screens for the recent use of drugs commonly found in the workplace, including opiates, cocaine, methamphetamine, and cannabis. With sample collection in seconds and results in under ten minutes, this technology would be a valuable tool for employers in safety-critical industries. The Company’s current customer segments outside the U.S. include construction, manufacturing and engineering, transport and logistics firms, mining, drug treatment organizations, and coroners.
For more information, visit:?https://ibs.inc/?
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties. Forward-looking statements in this press release include, without limitation, statements regarding Intelligent Bio Solutions Inc.’s ability to successfully develop and commercialize its drug and diagnostic tests, realize commercial benefits from its partnerships and collaborations, and secure regulatory clearance or approvals, among others. Although Intelligent Bio Solutions Inc. believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, actual results may differ materially from those expressed or implied by such statements. Intelligent Bio Solutions Inc. has attempted to identify forward-looking statements by terminology, including “believes,” “estimates,” “anticipates,” “expects,” “plans,” “projects,” “intends,” “potential,” “may,” “could,” “might,” “will,” “should,” and “approximately,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including those described in Intelligent Bio Solutions’ public filings with the U.S. Securities and Exchange Commission. Any forward-looking statements contained in this release speak only as of the date of this release. Intelligent Bio Solutions undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events.
Company Contact
Intelligent Bio Solutions Inc.?
info@ibs.inc
Investor & Media Contact
Valter Pinto, Managing Director?
KCSA Strategic Communications?
PH: (212) 896-1254?
INBS@kcsa.com
FAQ**
How does Intelligent Bio Solutions Inc. INBS plan to sustain its impressive year-over-year growth in reader sales and what strategies are in place to expand its customer base further in fiscal 2026?
Can Intelligent Bio Solutions Inc. INBS provide more detail on the expected increase in cartridge sales, particularly how the expanding installed base contributes to this growth?
What specific market segments does Intelligent Bio Solutions Inc. INBS target for its drug screening solutions, and how do these segments impact the overall revenue projections for fiscal Q2 2026?
How does Intelligent Bio Solutions Inc. INBS intend to leverage its technological advancements to enhance customer adoption and drive recurring revenue from its product categories in the coming quarters?
**MWN-AI FAQ is based on asking OpenAI questions about Intelligent Bio Solutions Inc. (NASDAQ: INBS).
NASDAQ: INBS
INBS Trading
-1.95% G/L:
$4.02 Last:
39,053 Volume:
$4.09 Open:
